Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Identifying stocks to buy and hold for decades rather than months or years can be difficult. The world and the economy are constantly changing, creating risks for long-term investors.

Antacid manufacturers stepped up their advertising efforts, introduced new products, and developed countless extensions for existing brands. At the same time, a new type of medication for treating ...

This company Being a consumer defensive stock ... later in the decade. However, Merck beat second-quarter estimates for earnings and sales. Products like Keytruda and Gardasil have been driving ...

The result helped Q2 revenue increase by 7% over the same period. Merck has a broader product portfolio with more than 52 drugs covering categories like vaccines, hospital acute care, cardiology ...

Merck MRK announced that it started the phase ... NVAMD and macular edema following retinal vein occlusion (RVO). Since the product launch in 2022, Vabysmo’s sales have been driven by strong ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

We have a factory that is almost finalized, and usually for cancer, those products are ready in six ... in combination with Merck's (NYSE:MRK) anti-PD1 therapy Keytruda in high-risk melanoma.

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...